Palatin Technologies, Inc. - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
PTN American 8731 https://www.palatin.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Palatin Technologies, Inc.

Q4 2024 Palatin Technologies Inc Earnings Call - Oct 2nd, 2024 10:54 am
Palatin Technologies Inc (PTN) Q4 2024 Earnings Call Transcript Highlights: Strategic Moves and ... - Oct 2nd, 2024 7:00 am
Palatin Reports Fourth Quarter and Fiscal Year Ended 2024 Financial Results, Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones - Oct 1st, 2024 11:30 am
Palatin to Report Fourth Quarter and Fiscal Year End 2024 Results - Sep 26th, 2024 11:30 am
Palatin Provides Update on Clinical Programs, Strategic Priorities, and Anticipated Milestones - Sep 9th, 2024 11:30 am
FDA Confirms Acceptability of Palatin's Remaining Phase 3 Pivotal Clinical Trials for PL9643 in Dry Eye Disease (DED) - Aug 28th, 2024 11:30 am
Palatin Technologies doses first subject in Phase II obesity treatment trial - Aug 23rd, 2024 8:52 am
First Patient Dosed in Phase 2 Clinical Study of Palatin's Bremelanotide Co-Administered with Tirzepatide (GLP-1) for the Treatment of Obesity - Aug 22nd, 2024 11:30 am
Palatin Announces Exercise of Warrants for Approximately $6.1 Million Gross Proceeds - Jun 21st, 2024 12:00 pm
Palatin initiates Bremelanotide-PDE5i Phase II trial for ED - Jun 21st, 2024 8:32 am
Palatin Announces the Initiation of a Phase 2 Clinical Study of Bremelanotide Co-Administered with a PDE5i for the Treatment of Erectile Dysfunction (ED) - Jun 20th, 2024 11:30 am
Palatin Technologies commences Phase II study of obesity treatment - Jun 13th, 2024 10:52 am
Palatin Initiates Phase 2 Clinical Study of Bremelanotide for the Treatment of Obesity - Jun 12th, 2024 11:30 am
Palatin Technologies (PTN) Upgraded to Buy: What Does It Mean for the Stock? - May 20th, 2024 4:00 pm
Palatin Technologies Inc (PTN) (Q3 2024) Earnings Call Transcript Highlights: Navigating ... - May 16th, 2024 7:05 am
Q3 2024 Palatin Technologies Inc Earnings Call - May 16th, 2024 5:46 am
Palatin Reports Third Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update - May 15th, 2024 11:30 am
Palatin to Report Third Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on May 15, 2024 - May 9th, 2024 11:30 am
Palatin Announces FDA Clearance of IND Application for the Co-Administration of Bremelanotide with Tirzepatide (GLP-1) for the Treatment of Obesity - May 2nd, 2024 11:30 am
Palatin to Host Virtual KOL Event "Beyond GLPs: The Multiple Roles for Novel Melanocortin Receptor 4 Agonists in Treating Obesity and Weight Loss Maintenance" on May 8, 2024 - Apr 30th, 2024 11:30 am